References
- Tängdén T, Karvanen M, Friberg LE, et al. Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments. Infect Dis (Lond). 2017;49:521–527.
- Hong DJ, Kim JO, Lee H, et al. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates. Diagn Microbiol Infect Dis. 2016;86:184–189.
- Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial disk susceptibility tests, CLSI M100 S27 (2017).
- Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67:1607–1615.
- Lim TP, Tan TY, Lee W, et al. In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One. 2011;6:e18485.
- Lee HJ, Bergen PJ, Bulitta JB, et al. Colistin and rifampicin combination: synergistic activity against multidrug-resistant Acinetobacter baumannii in an in vitro PK/PD model. Antimicrob Agents Chemother. 2013;2013:3738–3745.
- Nageeb W, Metwally L, Kamel M, et al. In vitro antimicrobial synergy studies of carbapenem-resistant Acinetobacter baumannii isolated from intensive care units of a tertiary care hospital in Egypt. J Infect Public Health. 2015;8:593–602.
- Bae S, Kim MC, Park SJ, et al. In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:6774–6779.
- MacNair CR, Stokes JM, Carfrae LA, et al. overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat Commun. 2018;9:458.
- Da Silva GJ, Domingues S. Interplay between colistin resistance, virulence and fitness in Acinetobacter baumannii. Antibiotics. 2017;6:28.